


CLAIMS (Clean-Form)

18. A compound selected from those of formula (I) :




wherein

- At
- ✓ R_1 , R_2 , R_3 and R_4 independently represent hydrogen, halogen or alkyl, alkoxy, hydroxy, alkylthio, mercapto, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or carbamoyl, or, taken in pairs, form together with the carbon atoms to which they are bonded a phenyl ring or an aromatic heterocycle having from 5 to 7 ring members and containing from 1 to 3 hetero atoms selected from nitrogen, oxygen and sulphur,
 - ✓ L_1 and L_2 each represents hydrogen or together form $-\text{CH}_2-\text{CH}_2-$,
 - ✓ X_1 , attached at the 2 or 3 position of the aromatic ring, represents a bond, and in that case X_2 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl), or, X_1 and X_2 , together with two adjacent carbon to which they are bonded in the 2, 3 or 4 position of the aromatic ring, form (C_4-C_7) cycloalkyl wherein one or two $-\text{CH}_2-$ of the cycloalkyl ring are optionally replaced by oxygen or NH (optionally substituted by alkyl) and wherein one carbon of the cycloalkyl ring is substituted by G,

- ✓ X_3 represents hydrogen, halogen, alkyl, alkoxy, hydroxy, nitro or cyano, or amino (optionally substituted by one or two alkyl),

G represents



wherein :

- BT
- ✓ the broken lines indicate the optional presence of a double bond,
 - ✓ Alk represents linear or branched (C_1 - C_6)alkylene wherein, when G_1 or G_2 contains imidazoline, the group Alk- is attached at the 2 position of the ring,
 - ✓ n is 0 or 1,
 - ✓ T_3 represents optionally substituted heteroaryl or optionally substituted heteroarylalkyl,

wherein :

- the term "alkyl" denotes linear or branched group containing from 1 to 6 carbon,
- the term "alkoxy" denotes linear or branched alkyl-oxy containing from 1 to 6 carbon,
- the term "aryl" denotes phenyl, naphthyl or biphenyl,
- the term "heteroaryl" denotes a benzodioxinyl group,
- the expression "optionally substituted" associated with aryl, arylalkyl, heteroaryl and heteroarylalkyl denotes that those groups are unsubstituted or substituted on the cyclic moiety by one or more halogen and/or alkyl, alkoxy, hydroxy, mercapto, alkylthio, cyano, amino (optionally substituted by one or two alkyl), nitro, carboxy, alkoxycarbonyl, aminocarbonyl (optionally substituted by one or two alkyl) or

B1
Sub
C1
carbamoyl, wherein heteroaryl and heteroarylalkyl may in addition be substituted by oxo, its

enantiomers and diastereoisomers thereof, and addition salts thereof with a pharmaceutically acceptable acid or base.

B2
Sub
E1
20. A compound of claim 18, wherein L₁ and L₂ together form -CH₂-CH₂-.

B3
Sub
E1
26. Compounds of claim 18, wherein R₃ and R₄ together with carbon to which they are bonded form a phenyl ring and L₁ and L₂ together form -CH₂-CH₂-.

B4
29. A compound of claim 18 that is *N*-(3-chloro-4-methylphenyl)-*N'*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}urea, its addition salts thereof with a pharmaceutically acceptable acid or base.

B5
Sub
E1
32. Compound of claim 18 that is *N*-{3-[4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-1-piperazinyl]phenyl}-*N'*-(3,4-dimethylphenyl)urea, its addition salts thereof with a pharmaceutically acceptable acid or base.

B6
Sub
E1
33. A method for treating an animal of human living body afflicted with depression, anxiety, schizophrenia, Parkinson's disease, cognitive disorders, libido disorders and sexual dysfunction, sleep disorders, drug abuse, and impulsive behaviour disorders comprising the step of administering to the living body an amount of a compound of claim 18 which is effective for alleviation of said condition.

34. A pharmaceutical composition useful for treating an animal of human living body afflicted with a condition selected from depression, anxiety, schizophrenia, Parkinson's disease, cognitive disorders, libido disorders and sexual dysfunction, sleep disorders,

Sub
E1

drug abuse, and impulsive behaviour disorders comprising a compound of claim 18 in combination with one or more pharmaceutically acceptable, excipients or vehicles.
